Inhaled Corticosteroid/Long-Acting Beta2-Agonist

Mechanism

Related News

AstraZeneca's Breztri Shows Positive Results in Phase III Asthma Trials

Mar 20, 2026

AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.

AstraZeneca's Breztri Shows Significant Improvement in Uncontrolled Asthma Patients

Feb 13, 2026

Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.